Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNabil F. Saba, Christine H. Chung, Ashley A. McCook‐Veal et al.|Nature Medicine|2023Cited by 76
1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 studyMatteo S Carlino, Bella Nguyen, Jia Liu et al.|Unknown|2025Cited by 0